tradingkey.logo
tradingkey.logo
Search

Arrowhead Pharmaceuticals Inc

ARWR
Add to Watchlist
80.500USD
+1.610+2.04%
Close 06/29, 16:00ETQuotes delayed by 15 min
11.34BMarket Cap
LossP/E TTM

TradingKey Stock Score of Arrowhead Pharmaceuticals Inc

Currency: USD Updated: 2026-06-29

Key Insights

Arrowhead Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 55 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.18.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arrowhead Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
55 / 387
Overall Ranking
137 / 4570
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Arrowhead Pharmaceuticals Inc Highlights

StrengthsRisks
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 244.55% year-on-year.
Undervalued
The company’s latest PE is -35.45, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 111.75M shares, decreasing 11.08% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.20.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
88.182
Target Price
+11.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Arrowhead Pharmaceuticals Inc?

The TradingKey Stock Score provides a comprehensive assessment of Arrowhead Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Arrowhead Pharmaceuticals Inc’s performance and outlook.

How do we generate the financial health score of Arrowhead Pharmaceuticals Inc?

To generate the financial health score of Arrowhead Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Arrowhead Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Arrowhead Pharmaceuticals Inc.

How do we generate the company valuation score of Arrowhead Pharmaceuticals Inc?

To generate the company valuation score of Arrowhead Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Arrowhead Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Arrowhead Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Arrowhead Pharmaceuticals Inc.

How do we generate the earnings forecast score of Arrowhead Pharmaceuticals Inc?

To calculate the earnings forecast score of Arrowhead Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Arrowhead Pharmaceuticals Inc’s future.

How do we generate the price momentum score of Arrowhead Pharmaceuticals Inc?

When generating the price momentum score for Arrowhead Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Arrowhead Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Arrowhead Pharmaceuticals Inc.

How do we generate the institutional confidence score of Arrowhead Pharmaceuticals Inc?

To generate the institutional confidence score of Arrowhead Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Arrowhead Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Arrowhead Pharmaceuticals Inc.

How do we generate the risk management score of Arrowhead Pharmaceuticals Inc?

To assess the risk management score of Arrowhead Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Arrowhead Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Arrowhead Pharmaceuticals Inc.
KeyAI